Global Alzheimer’s Treatment Market Outlook 2027
Alzheimer’s Treatment Market Analysis – 2019-2027
According to the Alzheimer’s Association in 2020, an estimated 5.8 million people above the age of 65 in America are living with Alzheimer’s disease. This number is further predicted to increase to 13.8 million people above the age of 65 by 2050. Alzheimer’s disease is a neurological disorder which commonly occurs among the older population. The disease is characterized by the gradual degeneration of the brain tissue, which leads to temporary or permanent loss of memory. The Alzheimer’s treatment market is anticipated to grow at a CAGR of about 7.44% over the forecast period, i.e., 2020-2027. The market is further projected to attain a market value of around USD 2,008.17 million by the end of 2027.
The market for Alzheimer’s treatment is segmented by drug class, by distribution channel, by product, by end user and by region. On the basis of distribution channel, the market is segmented into online and offline segment. The offline segment is further segmented into hospital pharmacy and retail pharmacy, out of which, the offline distribution channel is anticipated to hold the leading share in the market on account of larger presence of hospital and retail pharmacies globally. On the other hand, the segment for online distribution channel is predicted to grow at the highest CAGR during the forecast period on account of rising demand for online pharmacies and various advancements in the e-commerce industry. The preference for online pharmacies is estimated to increase among the patients on account of various factors such as ease and convenience, confidentiality, low cost, and others.
Based on region, the Alzheimer’s treatment market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in North America is anticipated to hold the major share of Alzheimer’s treatment market on account of increasing incidences of the disease. Moreover, the presence of key players in the region is another factor predicted to lead to the growth of North America Alzheimer’s treatment market in the coming years. The market in Europe is estimated to witness significant growth and hold a vast potential for the development of the Alzheimer’s treatment market on the back of its increasing geriatric population.
Some of the key industry leaders in the global Alzheimer’s treatment market are NeuroEM Therapeutics, Inc., AbbVie Inc., Allergan Inc., H. Lundbeck A/S, Janssen, Eli Lilly and Company, Daiichi Sankyo Company Limited, Eisai Co., Ltd. and Neuronix.
According to the Alzheimer’s Association in 2020, an estimated 5.8 million people above the age of 65 in America are living with Alzheimer’s disease. This number is further predicted to increase to 13.8 million people above the age of 65 by 2050. Alzheimer’s disease is a neurological disorder which commonly occurs among the older population. The disease is characterized by the gradual degeneration of the brain tissue, which leads to temporary or permanent loss of memory. The Alzheimer’s treatment market is anticipated to grow at a CAGR of about 7.44% over the forecast period, i.e., 2020-2027. The market is further projected to attain a market value of around USD 2,008.17 million by the end of 2027.
The market for Alzheimer’s treatment is segmented by drug class, by distribution channel, by product, by end user and by region. On the basis of distribution channel, the market is segmented into online and offline segment. The offline segment is further segmented into hospital pharmacy and retail pharmacy, out of which, the offline distribution channel is anticipated to hold the leading share in the market on account of larger presence of hospital and retail pharmacies globally. On the other hand, the segment for online distribution channel is predicted to grow at the highest CAGR during the forecast period on account of rising demand for online pharmacies and various advancements in the e-commerce industry. The preference for online pharmacies is estimated to increase among the patients on account of various factors such as ease and convenience, confidentiality, low cost, and others.
Based on region, the Alzheimer’s treatment market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The market in North America is anticipated to hold the major share of Alzheimer’s treatment market on account of increasing incidences of the disease. Moreover, the presence of key players in the region is another factor predicted to lead to the growth of North America Alzheimer’s treatment market in the coming years. The market in Europe is estimated to witness significant growth and hold a vast potential for the development of the Alzheimer’s treatment market on the back of its increasing geriatric population.
Some of the key industry leaders in the global Alzheimer’s treatment market are NeuroEM Therapeutics, Inc., AbbVie Inc., Allergan Inc., H. Lundbeck A/S, Janssen, Eli Lilly and Company, Daiichi Sankyo Company Limited, Eisai Co., Ltd. and Neuronix.
Global Alzheimer’s Treatment Market
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
1.3. Product Overview
2. ASSUMPTIONS AND ACRONYMS
3. RESEARCH METHODOLOGY
3.1. Research Process
3.2. Primary Research
Manufacturer Front
Supplier/Distributor Front
End User Front
3.3. Secondary Research
3.4. Market Size Estimation
4. EXECUTIVE SUMMARY- GLOBAL ALZHEIMER’S TREATMENT MARKET
5. ANALYSIS OF MARKET DYNAMICS
5.1. Growth Drivers
5.2. Key Trends
6. KEY MARKET OPPORTUNITIES
7. MAJOR ROADBLOCKS FOR THE MARKET GROWTH
8. REGULATORY LANDSCAPE
9. INDUSTRY RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. EPIDEMIOLOGY ANALYSIS
11. PATENT ANALYSIS
12. CLINICAL TRIALS ANALYSIS
13. COMPARATIVE ANALYSIS OF TREATMENT DEVICES IN DEVELOPMENT
14. GLOBAL ALZHEIMER’S TREATMENT MARKET OUTLOOK
14.1. Market Size And Forecast, 2018-2027
14.1.1. By Value (USD Million)
14.2. Global Alzheimer’s Treatment Market Segmentation, 2018-2027
14.2.1. By Treatment
14.2.1.1. By Drug Class
Standalone Drugs, 2018-2027 (USD Million)
Cholinesterase Inhibitors, 2018-2027 (USD Million)
Donepezil (Aricept), 2018-2027 (USD Million)
Galantamine (Razadyne), 2018-2027 (USD Million)
Rivastigmine (Exelon), 2018-2027 (USD Million)
N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
Combination Drugs, 2018-2027 (USD Million)
14.2.1.2. By Distribution Channel
Online, 2018-2027 (USD Million)
Offline, 2018-2027 (USD Million)
Hospital Pharmacy, 2018-2027 (USD Million)
Retail Pharmacy, 2018-2027 (USD Million)
14.2.2. By Medical Device
14.2.2.1. By Product
Wearable Device, 2018-2027 (USD Million)
Non-Wearable Device, 2018-2027 (USD Million)
14.2.2.2. By End-User
Hospitals, 2018-2027 (USD Million)
Clinics, 2018-2027 (USD Million)
Nursing Homes, 2018-2027 (USD Million)
Home-Care Settings, 2018-2027 (USD Million)
14.2.3. By Region
14.2.3.1. North America Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.1.1. Market Overview
14.2.3.1.2. Market Size, 2018-2027 (USD Million)
14.2.3.1.3. Assessment Of Macroeconomic Factors
14.2.3.1.4. Market Segmentation
By Treatment
By Drug Class
Standalone Drugs, 2018-2027 (USD Million)
Cholinesterase Inhibitors, 2018-2027 (USD Million)
Donepezil (Aricept), 2018-2027 (USD Million)
Galantamine (Razadyne), 2018-2027 (USD Million)
Rivastigmine (Exelon), 2018-2027 (USD Million)
N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
Combination Drugs, 2018-2027 (USD Million)
By Distribution Channel
Online, 2018-2027 (USD Million)
Offline, 2018-2027 (USD Million)
Hospital Pharmacy, 2018-2027 (USD Million)
Retail Pharmacy, 2018-2027 (USD Million)
By Medical Device
By Product
Wearable Device, 2018-2027 (USD Million)
Non-Wearable Device, 2018-2027 (USD Million)
By End-User
Hospitals, 2018-2027 (USD Million)
Clinics, 2018-2027 (USD Million)
Nursing Homes, 2018-2027 (USD Million)
Home-Care Settings, 2018-2027 (USD Million)
By Country
Us, 2018-2027 (USD Million)
Canada, 2018-2027 (USD Million)
14.2.3.2. Europe Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.2.1. Market Overview
14.2.3.2.2. Market Size, 2018-2027 (USD Million)
14.2.3.2.3. Assessment Of Macroeconomic Factors
14.2.3.2.4. Market Segmentation
By Treatment
By Drug Class
Standalone Drugs, 2018-2027 (USD Million)
Cholinesterase Inhibitors, 2018-2027 (USD Million)
Donepezil (Aricept), 2018-2027 (USD Million)
Galantamine (Razadyne), 2018-2027 (USD Million)
Rivastigmine (Exelon), 2018-2027 (USD Million)
N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
Combination Drugs, 2018-2027 (USD Million)
By Distribution Channel
Online, 2018-2027 (USD Million)
Offline, 2018-2027 (USD Million)
Hospital Pharmacy, 2018-2027 (USD Million)
Retail Pharmacy, 2018-2027 (USD Million)
By Medical Device
By Product
Wearable Device, 2018-2027 (USD Million)
Non-Wearable Device, 2018-2027 (USD Million)
By End-User
Hospitals, 2018-2027 (USD Million)
Clinics, 2018-2027 (USD Million)
Nursing Homes, 2018-2027 (USD Million)
Home-Care Settings, 2018-2027 (USD Million)
By Country
Uk, 2018-2027 (USD Million)
Germany, 2018-2027 (USD Million)
Italy, 2018-2027 (USD Million)
France, 2018-2027 (USD Million)
Spain, 2018-2027 (USD Million)
Russia, 2018-2027 (USD Million)
Rest Of Europe, 2018-2027 (USD Million)
14.2.3.3. Asia Pacific Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.3.1. Market Overview
14.2.3.3.2. Market Size, 2018-2027 (USD Million)
14.2.3.3.3. Assessment Of Macroeconomic Factors
14.2.3.3.4. Market Segmentation
By Treatment
By Drug Class
Standalone Drugs, 2018-2027 (USD Million)
Cholinesterase Inhibitors, 2018-2027 (USD Million)
Donepezil (Aricept), 2018-2027 (USD Million)
Galantamine (Razadyne), 2018-2027 (USD Million)
Rivastigmine (Exelon), 2018-2027 (USD Million)
N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
Combination Drugs, 2018-2027 (USD Million)
By Distribution Channel
Online, 2018-2027 (USD Million)
Offline, 2018-2027 (USD Million)
Hospital Pharmacy, 2018-2027 (USD Million)
Retail Pharmacy, 2018-2027 (USD Million)
By Medical Device
By Product
Wearable Device, 2018-2027 (USD Million)
Non-Wearable Device, 2018-2027 (USD Million)
By End-User
Hospitals, 2018-2027 (USD Million)
Clinics, 2018-2027 (USD Million)
Nursing Homes, 2018-2027 (USD Million)
Home-Care Settings, 2018-2027 (USD Million)
By Country
China, 2018-2027 (USD Million)
India, 2018-2027 (USD Million)
Japan, 2018-2027 (USD Million)
South Korea, 2018-2027 (USD Million)
Indonesia, 2018-2027 (USD Million)
Australia, 2018-2027 (USD Million)
Rest Of Asia Pacific, 2018-2027 (USD Million)
14.2.3.4. Latin America Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.4.1. Market Overview
14.2.3.4.2. Market Size, 2018-2027 (USD Million)
14.2.3.4.3. Assessment Of Macroeconomic Factors
14.2.3.4.4. Market Segmentation
By Treatment
By Drug Class
Standalone Drugs, 2018-2027 (USD Million)
Cholinesterase Inhibitors, 2018-2027 (USD Million)
Donepezil (Aricept), 2018-2027 (USD Million)
Galantamine (Razadyne), 2018-2027 (USD Million)
Rivastigmine (Exelon), 2018-2027 (USD Million)
N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
Combination Drugs, 2018-2027 (USD Million)
By Distribution Channel
Online, 2018-2027 (USD Million)
Offline, 2018-2027 (USD Million)
Hospital Pharmacy, 2018-2027 (USD Million)
Retail Pharmacy, 2018-2027 (USD Million)
By Medical Device
By Product
Wearable Device, 2018-2027 (USD Million)
Non-Wearable Device, 2018-2027 (USD Million)
By End-User
Hospitals, 2018-2027 (USD Million)
Clinics, 2018-2027 (USD Million)
Nursing Homes, 2018-2027 (USD Million)
Home-Care Settings, 2018-2027 (USD Million)
By Country
Brazil, 2018-2027 (USD Million)
Mexico, 2018-2027 (USD Million)
Rest Of Latin America, 2018-2027 (USD Million)
14.2.3.5. Middle East & Africa Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.5.1. Market Overview
14.2.3.5.2. Market Size, 2018-2027 (USD Million)
14.2.3.5.3. Assessment Of Macroeconomic Factors
14.2.3.5.4. Market Segmentation
By Treatment
By Drug Class
Standalone Drugs, 2018-2027 (USD Million)
Cholinesterase Inhibitors, 2018-2027 (USD Million)
Donepezil (Aricept), 2018-2027 (USD Million)
Galantamine (Razadyne), 2018-2027 (USD Million)
Rivastigmine (Exelon), 2018-2027 (USD Million)
N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
Combination Drugs, 2018-2027 (USD Million)
By Distribution Channel
By Product
By End-User
By Country
Israel, 2018-2027 (USD Million)
Saudi Arabia, 2018-2027 (USD Million)
UAE, 2018-2027 (USD Million)
South Africa, 2018-2027 (USD Million)
Rest Of Middle East & Africa, 2018-2027 (USD Million)
15. COMPETITIVE STRUCTURE
15.1. Detailed Overview
15.2. Market Share
15.3. Assessment Of Key Product Offerings
15.4. Analysis Of Growth Strategies
15.5. Key Collaborations And Joint Ventures
15.6. Key Mergers And Acquisitions
15.7. Recent News And Developments
15.8. Key Clients And Partners
15.9. Exhaustive Analysis On Key Financial Indicators
15.10. Company Profiles Of Global Alzheimer’s Treatment Market
15.10.1. Neuroem Therapeutics, Inc.
15.10.2. Neuronix
15.10.3. Daiichi Sankyo Company Limited
15.10.4. H. Lundbeck A/S
15.10.5. Pfizer Inc.
15.10.6. Abbvie Inc
15.10.7. Eli Lilly And Company
15.10.8. Allergan, Inc.
15.10.9. Janssen Pharmaceuticals, Inc.
15.10.10. Other Market Players Strategic 16. Recommendations
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
1.3. Product Overview
2. ASSUMPTIONS AND ACRONYMS
3. RESEARCH METHODOLOGY
3.1. Research Process
3.2. Primary Research
Manufacturer Front
Supplier/Distributor Front
End User Front
3.3. Secondary Research
3.4. Market Size Estimation
4. EXECUTIVE SUMMARY- GLOBAL ALZHEIMER’S TREATMENT MARKET
5. ANALYSIS OF MARKET DYNAMICS
5.1. Growth Drivers
5.2. Key Trends
6. KEY MARKET OPPORTUNITIES
7. MAJOR ROADBLOCKS FOR THE MARKET GROWTH
8. REGULATORY LANDSCAPE
9. INDUSTRY RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. EPIDEMIOLOGY ANALYSIS
11. PATENT ANALYSIS
12. CLINICAL TRIALS ANALYSIS
13. COMPARATIVE ANALYSIS OF TREATMENT DEVICES IN DEVELOPMENT
14. GLOBAL ALZHEIMER’S TREATMENT MARKET OUTLOOK
14.1. Market Size And Forecast, 2018-2027
14.1.1. By Value (USD Million)
14.2. Global Alzheimer’s Treatment Market Segmentation, 2018-2027
14.2.1. By Treatment
14.2.1.1. By Drug Class
Standalone Drugs, 2018-2027 (USD Million)
Cholinesterase Inhibitors, 2018-2027 (USD Million)
Donepezil (Aricept), 2018-2027 (USD Million)
Galantamine (Razadyne), 2018-2027 (USD Million)
Rivastigmine (Exelon), 2018-2027 (USD Million)
N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
Combination Drugs, 2018-2027 (USD Million)
14.2.1.2. By Distribution Channel
Online, 2018-2027 (USD Million)
Offline, 2018-2027 (USD Million)
Hospital Pharmacy, 2018-2027 (USD Million)
Retail Pharmacy, 2018-2027 (USD Million)
14.2.2. By Medical Device
14.2.2.1. By Product
Wearable Device, 2018-2027 (USD Million)
Non-Wearable Device, 2018-2027 (USD Million)
14.2.2.2. By End-User
Hospitals, 2018-2027 (USD Million)
Clinics, 2018-2027 (USD Million)
Nursing Homes, 2018-2027 (USD Million)
Home-Care Settings, 2018-2027 (USD Million)
14.2.3. By Region
14.2.3.1. North America Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.1.1. Market Overview
14.2.3.1.2. Market Size, 2018-2027 (USD Million)
14.2.3.1.3. Assessment Of Macroeconomic Factors
14.2.3.1.4. Market Segmentation
By Treatment
By Drug Class
Standalone Drugs, 2018-2027 (USD Million)
Cholinesterase Inhibitors, 2018-2027 (USD Million)
Donepezil (Aricept), 2018-2027 (USD Million)
Galantamine (Razadyne), 2018-2027 (USD Million)
Rivastigmine (Exelon), 2018-2027 (USD Million)
N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
Combination Drugs, 2018-2027 (USD Million)
By Distribution Channel
Online, 2018-2027 (USD Million)
Offline, 2018-2027 (USD Million)
Hospital Pharmacy, 2018-2027 (USD Million)
Retail Pharmacy, 2018-2027 (USD Million)
By Medical Device
By Product
Wearable Device, 2018-2027 (USD Million)
Non-Wearable Device, 2018-2027 (USD Million)
By End-User
Hospitals, 2018-2027 (USD Million)
Clinics, 2018-2027 (USD Million)
Nursing Homes, 2018-2027 (USD Million)
Home-Care Settings, 2018-2027 (USD Million)
By Country
Us, 2018-2027 (USD Million)
Canada, 2018-2027 (USD Million)
14.2.3.2. Europe Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.2.1. Market Overview
14.2.3.2.2. Market Size, 2018-2027 (USD Million)
14.2.3.2.3. Assessment Of Macroeconomic Factors
14.2.3.2.4. Market Segmentation
By Treatment
By Drug Class
Standalone Drugs, 2018-2027 (USD Million)
Cholinesterase Inhibitors, 2018-2027 (USD Million)
Donepezil (Aricept), 2018-2027 (USD Million)
Galantamine (Razadyne), 2018-2027 (USD Million)
Rivastigmine (Exelon), 2018-2027 (USD Million)
N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
Combination Drugs, 2018-2027 (USD Million)
By Distribution Channel
Online, 2018-2027 (USD Million)
Offline, 2018-2027 (USD Million)
Hospital Pharmacy, 2018-2027 (USD Million)
Retail Pharmacy, 2018-2027 (USD Million)
By Medical Device
By Product
Wearable Device, 2018-2027 (USD Million)
Non-Wearable Device, 2018-2027 (USD Million)
By End-User
Hospitals, 2018-2027 (USD Million)
Clinics, 2018-2027 (USD Million)
Nursing Homes, 2018-2027 (USD Million)
Home-Care Settings, 2018-2027 (USD Million)
By Country
Uk, 2018-2027 (USD Million)
Germany, 2018-2027 (USD Million)
Italy, 2018-2027 (USD Million)
France, 2018-2027 (USD Million)
Spain, 2018-2027 (USD Million)
Russia, 2018-2027 (USD Million)
Rest Of Europe, 2018-2027 (USD Million)
14.2.3.3. Asia Pacific Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.3.1. Market Overview
14.2.3.3.2. Market Size, 2018-2027 (USD Million)
14.2.3.3.3. Assessment Of Macroeconomic Factors
14.2.3.3.4. Market Segmentation
By Treatment
By Drug Class
Standalone Drugs, 2018-2027 (USD Million)
Cholinesterase Inhibitors, 2018-2027 (USD Million)
Donepezil (Aricept), 2018-2027 (USD Million)
Galantamine (Razadyne), 2018-2027 (USD Million)
Rivastigmine (Exelon), 2018-2027 (USD Million)
N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
Combination Drugs, 2018-2027 (USD Million)
By Distribution Channel
Online, 2018-2027 (USD Million)
Offline, 2018-2027 (USD Million)
Hospital Pharmacy, 2018-2027 (USD Million)
Retail Pharmacy, 2018-2027 (USD Million)
By Medical Device
By Product
Wearable Device, 2018-2027 (USD Million)
Non-Wearable Device, 2018-2027 (USD Million)
By End-User
Hospitals, 2018-2027 (USD Million)
Clinics, 2018-2027 (USD Million)
Nursing Homes, 2018-2027 (USD Million)
Home-Care Settings, 2018-2027 (USD Million)
By Country
China, 2018-2027 (USD Million)
India, 2018-2027 (USD Million)
Japan, 2018-2027 (USD Million)
South Korea, 2018-2027 (USD Million)
Indonesia, 2018-2027 (USD Million)
Australia, 2018-2027 (USD Million)
Rest Of Asia Pacific, 2018-2027 (USD Million)
14.2.3.4. Latin America Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.4.1. Market Overview
14.2.3.4.2. Market Size, 2018-2027 (USD Million)
14.2.3.4.3. Assessment Of Macroeconomic Factors
14.2.3.4.4. Market Segmentation
By Treatment
By Drug Class
Standalone Drugs, 2018-2027 (USD Million)
Cholinesterase Inhibitors, 2018-2027 (USD Million)
Donepezil (Aricept), 2018-2027 (USD Million)
Galantamine (Razadyne), 2018-2027 (USD Million)
Rivastigmine (Exelon), 2018-2027 (USD Million)
N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
Combination Drugs, 2018-2027 (USD Million)
By Distribution Channel
Online, 2018-2027 (USD Million)
Offline, 2018-2027 (USD Million)
Hospital Pharmacy, 2018-2027 (USD Million)
Retail Pharmacy, 2018-2027 (USD Million)
By Medical Device
By Product
Wearable Device, 2018-2027 (USD Million)
Non-Wearable Device, 2018-2027 (USD Million)
By End-User
Hospitals, 2018-2027 (USD Million)
Clinics, 2018-2027 (USD Million)
Nursing Homes, 2018-2027 (USD Million)
Home-Care Settings, 2018-2027 (USD Million)
By Country
Brazil, 2018-2027 (USD Million)
Mexico, 2018-2027 (USD Million)
Rest Of Latin America, 2018-2027 (USD Million)
14.2.3.5. Middle East & Africa Alzheimer’s Treatment Market, 2018-2027 (USD Million)
14.2.3.5.1. Market Overview
14.2.3.5.2. Market Size, 2018-2027 (USD Million)
14.2.3.5.3. Assessment Of Macroeconomic Factors
14.2.3.5.4. Market Segmentation
By Treatment
By Drug Class
Standalone Drugs, 2018-2027 (USD Million)
Cholinesterase Inhibitors, 2018-2027 (USD Million)
Donepezil (Aricept), 2018-2027 (USD Million)
Galantamine (Razadyne), 2018-2027 (USD Million)
Rivastigmine (Exelon), 2018-2027 (USD Million)
N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)
Combination Drugs, 2018-2027 (USD Million)
By Distribution Channel
By Product
By End-User
By Country
Israel, 2018-2027 (USD Million)
Saudi Arabia, 2018-2027 (USD Million)
UAE, 2018-2027 (USD Million)
South Africa, 2018-2027 (USD Million)
Rest Of Middle East & Africa, 2018-2027 (USD Million)
15. COMPETITIVE STRUCTURE
15.1. Detailed Overview
15.2. Market Share
15.3. Assessment Of Key Product Offerings
15.4. Analysis Of Growth Strategies
15.5. Key Collaborations And Joint Ventures
15.6. Key Mergers And Acquisitions
15.7. Recent News And Developments
15.8. Key Clients And Partners
15.9. Exhaustive Analysis On Key Financial Indicators
15.10. Company Profiles Of Global Alzheimer’s Treatment Market
15.10.1. Neuroem Therapeutics, Inc.
15.10.2. Neuronix
15.10.3. Daiichi Sankyo Company Limited
15.10.4. H. Lundbeck A/S
15.10.5. Pfizer Inc.
15.10.6. Abbvie Inc
15.10.7. Eli Lilly And Company
15.10.8. Allergan, Inc.
15.10.9. Janssen Pharmaceuticals, Inc.
15.10.10. Other Market Players Strategic 16. Recommendations
